Optimal suppression of thromboxane A2 formation by aspirin during percutaneous transluminal coronary angioplasty: No additional effect of a selective cyclooxygenase-2 inhibitor

Journal of the American College of Cardiology

Volumn 43, Issue 4, 2004, Pages 526-531

  Kearney, Dermot ^a   Byrne, Anthony ^a   Crean, Peter ^b   Cox, Dermot ^a   Fitzgerald, Desmond J ^a  

^a ROYAL COLLEGE OF SURGEONS IN IRELAND   (Ireland)

^b ST JAMES S HOSPITAL   (Ireland)

Author keywords

11 dehydro TxB2; 2,3 dinor 6 keto PGF 1 ; Cyclooxygenase; Glycoprotein; Myocardial infarction; Non steroidal anti inflammatory drug; Percutaneous transluminal coronary angioplasty; Prostacyclin; Prostaglandin; Thromboxane

Indexed keywords

8 EPI PROSTAGLANDIN F2ALPHA; 8 ISOPROSTAGLANDIN F2 ALPHA; 8-EPI-PROSTAGLANDIN F2ALPHA; ACETYLSALICYLIC ACID; ANTITHROMBOCYTIC AGENT; BIPHENYL DERIVATIVE; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITOR; DRUG DERIVATIVE; FIBRINOGEN RECEPTOR; FIBRINOGEN RECEPTOR ANTAGONIST; FRADAFIBAN; ISOENZYME; NIMESULIDE; PEROXIDASE; PROSTACYCLIN; PROSTAGLANDIN F2 ALPHA; PROSTAGLANDIN SYNTHASE; PYRROLIDINE DERIVATIVE; SULFONAMIDE; THROMBOXANE A2; UNCLASSIFIED DRUG;

ADULT; ARTICLE; BIOSYNTHESIS; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; ENZYME ACTIVITY; ENZYME INHIBITION; EXCRETION; FEMALE; HUMAN; LIPOGENESIS; MALE; METABOLITE; PHYSIOLOGY; PRIORITY JOURNAL; PRODUCTIVITY; PROTEIN FUNCTION; PROTEIN SECRETION; PROTEIN SYNTHESIS INHIBITION; RANDOMIZED CONTROLLED TRIAL; RESTENOSIS; THROMBOSIS; TRANSLUMINAL CORONARY ANGIOPLASTY; URINALYSIS; URINE;

EID: 1242295208     PISSN: 07351097     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jacc.2003.09.041     Document Type: Article

References (38)

1. Moncada S., Vane J.R. Arachidonic acid metabolites and the interactions between platelets and blood vessel walls. N Engl J Med. 300:1979;1142-1147.
2. Lawson J.A., Rokach J., FitzGerald G.A. Isoprostanes Formation, analysis and use as indices of lipid peroxidation in vivo . J Biol Chem. 274:1999;24441-24444.
3. Hamberg M., Svensson J., Samuelsson B. Thromboxanes A new group of biologically active compounds derived from prostaglandin endoperoxides . Proc Natl Acad Sci U S A. 72:1975;2994-2998.
4. 2 . Science. 193:1976;1135-1137.
5. 2 receptors Measurement of u46619-induced calcium efflux . Circ Res. 60:1987;952-956.
6. 2 in vascular smooth muscle cells. Biochem Pharmacol. 40:1990;2535-2542.
7. Moncada S., Gryglewski R., Bunting S., Vane J.R. An enzyme isolated from arteries transforms prostaglandin endoperoxides to an unstable substance that inhibits platelet aggregation. Nature. 263:1976;663-665.
8. Xi W.L., Chapman J.G., Robertson D.L., Erikson R.L., Simmons D.L. Expression of a miotgen-responsive gene encoding prostaglandin synthase is regulated by mRNA splicing. J Biol Chem. 88:1991;2692-2696.
9. O'Neill G., Ford-Hutchinson A.W. Expression of mRNA for cyclooxygenase-1 and cyclooxygenase-2 in human tissues. FEBS Lett. 330:1993;156-160.
10. Cipollone F., Patrignani P., Greco A., et al. Differential suppression of thromboxane biosynthesis by indobufen and aspirin in patients with unstable angina. Circulation. 96:1997;1109-1116.
11. Adderley S., Fitzgerald D.J. Oxidative damage of cardiomyocytes is limited by ERK1/2-mediated induction of cyclooxygenase-2. J Biol Chem. 274:1999;5038-5046.
12. Jones D.A., Carlton D.P., McIntyre T.M., Zimmerman G.A., Prescott S.M. Molecular cloning of human endoperoxide synthase type II and demonstration of expression in response to cytokines. J Biol Chem. 268:1993;9049-9054.
13. Vinals M., Martinez-Gonzalez J., Badimon J.J., Badimon L. HDL-induced prostacyclin release in smooth muscle cells is dependent on cyclooxygenase-2 (Cox-2). Arterioscler Thromb Vasc Biol. 17:1997;3481-3488.
14. Bishop-Bailey D., Pepper J.R., Larkin S.W., Mitchell J.A. Differential induction of cyclooxygenase-2 in human arterial and venous smooth muscle. Arterioscler Thromb Vasc Biol. 18:1998;1655-1661.
15. Crofford L.J., Wilder R.L., Ristimaki A.P., et al. Cyclooxygenase-1 and -2 expression in rheumatoid synovial tissues: effects of interleukin-1β, phorbol ester and corticosteroids. J Clin Invest. 93:1994;1095-1101.
16. Sheehan K.M., Sheahan K., O'Donoghue D.P., et al. The relationship between cyclooxygenase-2 expression and colorectal cancer. JAMA. 282:1999;1254-1257.
17. Cullen L., Kelly L., O'Connor S., Fitzgerald D.J. Selective cyclooxygenase-2 inhibition by nimesulide in man. J Pharmacol Exp Ther. 287:1998;578-582.
18. McAdam B.F., Catella-Lawson F., Mardini I.A., Kapoor S., Lawson J.A., FitzGerald G. Systemic biosynthesis of prostacyclin by cyclooxygenase-2. The human pharmacology of a selective inhibitor of Cox-2. Proc Natl Acad Sci U S A. 96:1999;272-277.
19. Morrow J.D., Roberts L.J. II. The isoprostanes Current knowledge and directions for future research . Biochem Pharmacol. 51:1996;1-9.
20. 2α. J Biol Chem. 270:1995;9800-9808.
21. 2-isoprostane formation. Br J Pharmacol. 118:1996;1285-1293.
22. 2 biosynthesis in cardiovascular disease. Circulation. 67:1983;1174-1177.
23. Fitzgerald D.J., Roy L., Catella F., FitzGerald G.A. Platelet activation in unstable coronary disease. N Engl J Med. 315:1986;983-989.
24. 2-isoprostanes in human atherosclerotic lesions. J Clin Invest. 100:1997;2028-2034.
25. 2 formation despite administration of a platelet glycoprotein IIb/IIIa antagonist in patients undergoing coronary angioplasty. Arterioscler Thromb Vasc Biol. 17:1997;3224-3229.
26. Braden G.A., Knapp H.R., FitzGerald G. Suppression of eicosanoid biosynthesis during coronary angioplasty by fish oil and aspirin. Circulation. 84:1991;679-685.
27. 2α in acute coronary angioplasty. Circulation. 96:1997;3314-3320.
28. Warner T.D., Giuiliano F., Vojnovic I., Bukasa A., Mitchell J.A., Vane J.R. Non-steroid drug selectivities for cyclo-oxygenase-1 rather than cyclo-oxygenase-2 are associated with human gastrointestinal toxicity A full in vitro analysis . Proc Natl Acad Sci U S A. 96:1999;7563-7568.
29. Schwartz L., Bourassa M.G., Lesperance J., et al. Aspirin and dipyridamole in the prevention of restenosis after percutaneous transluminal coronary angioplasty. N Engl J Med. 318:1988;1714-1719.
30. Baker C.S., Hall R.J., Evans T.J., et al. Cyclooxygenase-2 is widely expressed in atherosclerotic lesions affecting native and transplanted human coronary arteries and colocalizes with inducible nitric oxide synthase and nitrotyrosine particularly in macrophages. Arterioscler Thromb Vasc Biol. 19:1999;646-655.
31. Karim S., Habib A., Levy-Toledano S., Maclouf J. Cyclooxygenase-1 and -2 of endothelial cells utilize exogenous or endogenous arachidonic acid for transcellular production of thromboxane. J Biol Chem. 17:1996;12042-12048.
32. Williams R.L. A note on robust variance estimation for cluster-correlated data. Biometrics. 56:2000;645-646.
33. Belton O., Byrne D., Kearney D., Leahy A.L., Fitzgerald D.J. Cyclooxygenase-1 and cyclooxygenase-2 dependent prostacyclin formation in patients with atherosclerosis. Circulation. 102:2000;840-845.
34. Connolly E., Bouchier-Hayes D.J., Kaye E., Leahy A., Fitzgerald D., Belton O. Cyclooxygenase isozyme expression and intimal hyperplasia in a rat model of balloon angioplasty. J Pharmacol Exp Ther. 300:2002;393-398.
35. 2 but not of systemic prostacyclin by controlled-release aspirin. N Engl J Med. 325:1991;1137-1141.
36. Shah A.A., Thjodleifsson B., Murray F.E., et al. Selective inhibition of COX-2 in humans is associated with less gastrointestinal injury A comparison of nimesulide and naproxen . Gut. 48:2001;339-346.
37. Patrono C., FitzGerald G. Isoprostanes Potential markers of oxidant stress in atherothrombotic disease . Arterioscler Thromb Vasc Biol. 17:1997;2309-2315.
38. Pratico D., Tangirala R.K., Rader D.J., Rokach J., FitzGerald G. Vitamin E suppresses isoprostane generation in vivo and reduces atherosclerosis in ApoE-deficient mice. Nat Med. 4:1998;1189-1192.